Published in PLoS One on July 05, 2013
RBR E3 ubiquitin ligases: new structures, new insights, new questions. Biochem J (2014) 1.13
Parkin structure and function. FEBS J (2015) 0.80
UbMES and UbFluor: Novel Probes For RBR E3 Ubiquitin Ligase PARKIN. J Biol Chem (2017) 0.75
Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell (2000) 7.82
Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem (2000) 6.87
Ubiquitin-binding domains. Nat Rev Mol Cell Biol (2005) 6.77
Refined structure of human carbonic anhydrase II at 2.0 A resolution. Proteins (1988) 4.32
A 'rule of three' for fragment-based lead discovery? Drug Discov Today (2003) 3.45
Do structurally similar molecules have similar biological activity? J Med Chem (2002) 3.29
Autoregulation of Parkin activity through its ubiquitin-like domain. EMBO J (2011) 2.75
Mechanistic insight into the allosteric activation of a ubiquitin-conjugating enzyme by RING-type ubiquitin ligases. Proc Natl Acad Sci U S A (2005) 2.60
Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets (2011) 2.58
Is there a difference between leads and drugs? A historical perspective. J Chem Inf Comput Sci (2001) 2.38
Fragment-based drug discovery. J Med Chem (2004) 2.07
The role of parkin in familial and sporadic Parkinson's disease. Mov Disord (2010) 1.90
Control of biochemical reactions through supramolecular RING domain self-assembly. Proc Natl Acad Sci U S A (2002) 1.63
Ligand binding efficiency: trends, physical basis, and implications. J Med Chem (2008) 1.59
How does parkin ligate ubiquitin to Parkinson's disease? EMBO Rep (2004) 1.54
Self-assembly properties of a model RING domain. Proc Natl Acad Sci U S A (2002) 1.46
Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination. Science (2011) 1.32
Crystallization of glutathione S-transferase from human placenta. J Mol Biol (1990) 1.18
Aberrant folding of pathogenic Parkin mutants: aggregation versus degradation. J Biol Chem (2008) 1.07
From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance. Methods Enzymol (2011) 1.06
Crystal structure and molecular dynamics simulation of ubiquitin-like domain of murine parkin. Biochim Biophys Acta (2008) 1.05
Small, N-terminal tags activate Parkin E3 ubiquitin ligase activity by disrupting its autoinhibited conformation. PLoS One (2012) 0.95
Fragment screening by surface plasmon resonance. ACS Med Chem Lett (2010) 0.93
High-throughput screening for inhibitors of the e3 ubiquitin ligase APC. Methods Enzymol (2005) 0.92
Parkin, A Top Level Manager in the Cell's Sanitation Department. Open Biochem J (2011) 0.89
Fragment library screening and lead characterization using SPR biosensors. Curr Top Med Chem (2009) 0.88
Fragment-based screening using surface plasmon resonance technology. J Biomol Screen (2009) 0.87
Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification. J Biomol Screen (2010) 0.84
Novel approach for characterizing ubiquitin E3 ligase function. J Biomol Screen (2010) 0.82
Label-free kinetic binding data as a decisive element in drug discovery. Expert Opin Drug Discov (2006) 0.81
Quantitative assays of Mdm2 ubiquitin ligase activity and other ubiquitin-utilizing enzymes for inhibitor discovery. Methods Enzymol (2005) 0.78
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity. Cell (2010) 5.83
Nuclear-localized BZR1 mediates brassinosteroid-induced growth and feedback suppression of brassinosteroid biosynthesis. Dev Cell (2002) 4.83
Direct activation of protein kinases by unanchored polyubiquitin chains. Nature (2009) 4.65
Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem (2006) 4.06
The GSK3-like kinase BIN2 phosphorylates and destabilizes BZR1, a positive regulator of the brassinosteroid signaling pathway in Arabidopsis. Proc Natl Acad Sci U S A (2002) 3.26
A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol (2005) 2.51
Autophagy is an adaptive response in desmin-related cardiomyopathy. Proc Natl Acad Sci U S A (2008) 2.07
Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure (2004) 1.84
Amplification efficiency of thermostable DNA polymerases. Anal Biochem (2003) 1.81
Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol (2005) 1.79
Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis (2008) 1.77
Comprehensive and quantitative mapping of energy landscapes for protein-protein interactions by rapid combinatorial scanning. J Biol Chem (2006) 1.59
Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors. Nucleic Acids Res (2003) 1.50
Inhibition of transforming growth factor-beta1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress. Cancer Res (2006) 1.42
Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem (2005) 1.33
Human genetic disease caused by de novo mitochondrial-nuclear DNA transfer. Hum Genet (2003) 1.31
Activity of the isolated HIV RNase H domain and specific inhibition by N-hydroxyimides. Biochem Biophys Res Commun (2004) 1.27
Ric-8A catalyzes guanine nucleotide exchange on G alphai1 bound to the GPR/GoLoco exchange inhibitor AGS3. J Biol Chem (2008) 1.19
Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity. Mol Pharmacol (2004) 1.18
Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus. J Biol Chem (2009) 1.17
Ca2+/calmodulin-dependent protein kinase II-dependent remodeling of Ca2+ current in pressure overload heart failure. J Biol Chem (2008) 1.16
BCOR analysis in patients with OFCD and Lenz microphthalmia syndromes, mental retardation with ocular anomalies, and cardiac laterality defects. Eur J Hum Genet (2009) 1.15
Case reports of oculofaciocardiodental syndrome with unusual dental findings. Am J Med Genet A (2005) 1.12
Energetic contribution of residues in the Runx1 Runt domain to DNA binding. J Biol Chem (2003) 1.12
Comprehensive gene expression analysis by transcript profiling. Plant Mol Biol (2002) 1.10
Proximity-induced catalysis by the protein kinase ERK2. J Am Chem Soc (2005) 1.08
Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS. PLoS One (2012) 1.07
Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes. Bioconjug Chem (2014) 1.05
Biochemical characterization of recombinant hepatitis C virus nonstructural protein 4B: evidence for ATP/GTP hydrolysis and adenylate kinase activity. Biochemistry (2009) 1.05
Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs). Biochem Biophys Res Commun (2006) 1.04
Ursodeoxycholic acid and F(6)-D(3) inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin. Cancer Epidemiol Biomarkers Prev (2002) 1.01
A peptide core motif for binding to heterotrimeric G protein alpha subunits. J Biol Chem (2005) 0.98
Cardiac troponin I mutations in Australian families with hypertrophic cardiomyopathy: clinical, genetic and functional consequences. J Mol Cell Cardiol (2005) 0.96
Remodeling of outward K+ currents in pressure-overload heart failure. J Cardiovasc Electrophysiol (2007) 0.95
Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol (2006) 0.95
The effect of arrestin conformation on the recruitment of c-Raf1, MEK1, and ERK1/2 activation. PLoS One (2011) 0.95
Identification of Cys255 in HIF-1α as a novel site for development of covalent inhibitors of HIF-1α/ARNT PasB domain protein-protein interaction. Protein Sci (2012) 0.94
Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease. J Biol Chem (2009) 0.94
Dual-energy computed tomography imaging of thyroid nodule specimens: comparison with pathologic findings. Invest Radiol (2012) 0.93
Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human beta-secretase. J Med Chem (2007) 0.92
Progression of left ventricular hypertrophy and the angiotensin-converting enzyme gene polymorphism in hypertrophic cardiomyopathy. Int J Cardiol (2004) 0.92
Design, synthesis, and structure-activity relationship of novel orally efficacious pyrazole/sulfonamide based dihydroquinoline gamma-secretase inhibitors. Bioorg Med Chem Lett (2009) 0.91
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. Proc Natl Acad Sci U S A (2013) 0.91
Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease. Alzheimers Res Ther (2010) 0.91
Perinatal screening for group B streptococci: cost-benefit analysis of rapid polymerase chain reaction. Pediatrics (2002) 0.91
Mutagenesis of the Runt domain defines two energetic hot spots for heterodimerization with the core binding factor beta subunit. J Biol Chem (2003) 0.90
Molecular insights from a novel cardiac troponin I mouse model of familial hypertrophic cardiomyopathy. J Mol Cell Cardiol (2006) 0.90
Trans-Zeatin attenuates ultraviolet induced down-regulation of aquaporin-3 in cultured human skin keratinocytes. Int J Mol Med (2010) 0.90
RAMPED-UP NMR: multiplexed NMR-based screening for drug discovery. J Am Chem Soc (2003) 0.89
Synergistic action of dietary phyto-antioxidants on survival and proliferation of ovarian cancer cells. Gynecol Oncol (2008) 0.89
Aging is not associated with proteasome impairment in UPS reporter mice. PLoS One (2009) 0.88
A novel shape-feature based approach to virtual library screening. J Chem Inf Comput Sci (2002) 0.88
Design of substrate-based inhibitors of human beta-secretase. J Med Chem (2002) 0.87
Selective and brain-permeable polo-like kinase-2 (Plk-2) inhibitors that reduce α-synuclein phosphorylation in rat brain. ChemMedChem (2013) 0.87
Perlecan domain V inhibits α2 integrin-mediated amyloid-β neurotoxicity. Neurobiol Aging (2010) 0.86
Brain tissue- and region-specific abnormalities on volumetric MRI scans in 21 patients with Bardet-Biedl syndrome (BBS). BMC Med Genet (2011) 0.86
MicroRNA-29a-c decrease fasting blood glucose levels by negatively regulating hepatic gluconeogenesis. J Hepatol (2012) 0.86
A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo. J Biol Chem (2005) 0.85
Design and synthesis of a novel, orally active, brain penetrant, tri-substituted thiophene based JNK inhibitor. Bioorg Med Chem Lett (2011) 0.85
Design and synthesis of cell potent BACE-1 inhibitors: structure-activity relationship of P1' substituents. Bioorg Med Chem Lett (2009) 0.85
Thermodynamic and kinetic characterization of hydroxyethylamine β-secretase-1 inhibitors. Biochem Biophys Res Commun (2013) 0.84
Shapes of things: computer modeling of molecular shape in drug discovery. Curr Top Med Chem (2007) 0.84
Comparing probability and non-probability sampling methods in Ecstasy research: implications for the internet as a research tool. Subst Use Misuse (2010) 0.84
Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration. Bioorg Med Chem Lett (2010) 0.83
Cyclic amide bioisosterism: strategic application to the design and synthesis of HCV NS5B polymerase inhibitors. Bioorg Med Chem Lett (2010) 0.83
Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK. Bioorg Med Chem Lett (2010) 0.83
Including explicit water molecules as part of the protein structure in MM/PBSA calculations. J Chem Inf Model (2014) 0.83
Discovery and structure-activity relationships of modified salicylanilides as cell permeable inhibitors of poly(ADP-ribose) glycohydrolase (PARG). J Med Chem (2011) 0.83
Ursodeoxycholic acid inhibits the initiation and postinitiation phases of azoxymethane-induced colonic tumor development. Cancer Epidemiol Biomarkers Prev (2002) 0.83
Differential attenuation of clavicle growth after asymmetric mantle radiotherapy. Int J Radiat Oncol Biol Phys (2004) 0.83
Contemporary cocaine use patterns and associated harms in Melbourne and Sydney, Australia. Drug Alcohol Rev (2007) 0.82
Alzheimer's disease amyloid beta and prion protein amyloidogenic peptides promote macrophage survival, DNA synthesis and enhanced proliferative response to CSF-1 (M-CSF). Brain Res (2002) 0.81
Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett (2010) 0.81
Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents. J Med Chem (2002) 0.81
Factors associated with driving under the influence of alcohol and drugs among an Australian sample of regular ecstasy users. Drug Alcohol Depend (2008) 0.81
High throughput method for the indirect detection of intramolecular hydrogen bonding. J Med Chem (2014) 0.81
ID NMR Methods in ligand-receptor interactions. Curr Top Med Chem (2003) 0.80
Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region. Bioorg Med Chem Lett (2010) 0.80
Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints. J Med Chem (2004) 0.80